Meeting
2021 ASCO Annual Meeting
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
Authors
Hamzah Abu-Sbeih
University of Missouri, Kansas City, MO
Hamzah Abu-Sbeih , Tenglong Tang , David M. Faleck , Michael L. Dougan , Anna Olsson-Brown , Douglas Buckner Johnson , Dwight Hall Owen , David Engar Warner , Alexander B Philipp , Nick Powell , Ella Daniels , Jessica Philpott , Alison Margaret Weppler , David James Pinato , Yinghong Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2643)
DOI
10.1200/JCO.2021.39.15_suppl.2643
Abstract #
2643
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis.
First Author: Hamzah Abu-Sbeih
Poster
2023 ASCO Annual Meeting
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.
First Author: Hamzah Abu-Sbeih
Poster
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
First Author: Joan Miguel Romero
Poster
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
First Author: Catriona Harvey